US2021069333A1PendingUtilityA1

Cannabinoids in combination with non-cannabinoid chemotherapeutic agents

60
Assignee: GW PHARMA LTDPriority: Jun 4, 2008Filed: Nov 23, 2020Published: Mar 11, 2021
Est. expiryJun 4, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Guillermo Velasco DiezManuel Guzman PastorMar LorenteSofia Torres
A61K 31/658A61P 35/00A61K 31/53A61K 31/138A61K 31/282A61K 31/05A61K 45/06A61K 31/185A61K 31/17A61K 31/4535A61P 25/00A61P 43/00A61K 31/352
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method for treating glioma in a human in need thereof, comprising: administering to the human:
 (i) tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:20; and   (ii) temozolomide.   
     
     
         22 . The method of  claim 21 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:5. 
     
     
         23 . The method of  claim 21 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:2. 
     
     
         24 . The method of  claim 21 , wherein a botanical drug substance comprising the THC and CBD is administered to the human. 
     
     
         25 . The method of  claim 21 , wherein the human has a glioma tumour. 
     
     
         26 . The method of  claim 25 , wherein the glioma tumour is glioblastoma multiforme (GBM). 
     
     
         27 . The method of  claim 21 , wherein the THC and CBD, and the temozolomide are administered separately. 
     
     
         28 . The method of  claim 21 , wherein the THC and CBD, and the temozolomide are administered sequentially. 
     
     
         29 . The method of  claim 21 , wherein the THC and CBD, and the temozolomide are administered simultaneously. 
     
     
         30 . A method for increasing the efficacy of temozolomide in inhibiting cancer cell growth or reducing cancer cell viability comprising: administering to a human having a glioma tumour:
 (i) a botanical drug substance comprising tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:20; and   (ii) temozolomide.   
     
     
         31 . The method of  claim 30 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:5. 
     
     
         32 . The method of  claim 30 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:2. 
     
     
         33 . The method of  claim 30 , wherein the glioma tumour is a glioblastoma multiforme (GBM). 
     
     
         34 . The method of  claim 30 , wherein the THC and CBD, and the temozolomide are administered separately. 
     
     
         35 . The method of  claim 30 , wherein the THC and CBD, and the temozolomide are administered sequentially. 
     
     
         36 . The method of  claim 30 , wherein the THC and CBD, and the temozolomide are administered simultaneously.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.